Photo from wikipedia
Immune‐related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) are often managed via immunosuppressive agents (ISAs); however, their impact on ICI efficacy is not well studied. The impact of… Click to show full abstract
Immune‐related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) are often managed via immunosuppressive agents (ISAs); however, their impact on ICI efficacy is not well studied. The impact of the use of ISAs on ICI efficacy in patients with advanced melanoma was therefore investigated.
Keywords:
advanced melanoma;
immune checkpoint;
patients advanced;
efficacy patients;
efficacy;
immunosuppressive agents
Journal Title: Cancer
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!